Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):1922–1925. doi: 10.1128/aac.41.9.1922

Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine.

M Iten 1, H Mett 1, A Evans 1, J C Enyaru 1, R Brun 1, R Kaminsky 1
PMCID: PMC164036  PMID: 9303385

Abstract

Ornithine decarboxylase (ODC), the target enzyme of D,L-alpha-difluoromethylornithine (DFMO), was investigated in four DFMO-tolerant Trypanosoma brucei rhodesiense isolates from East Africa and two DFMO-susceptible T. b. gambiense isolates from West Africa. Neither drug uptake nor inhibition of ODC activity by DFMO in cellular extracts differed in the two trypanosome subspecies. However, the specific ODC activity of the cellular extracts was three times as high in T. b. rhodesiense isolates as in T. b. gambiense isolates. Furthermore, a significant difference in the turnover rate of ODC was observed. The time required to induce a 50% reduction of T. b. rhodesiense ODC activity under cycloheximide pressure (tentative half-life) was about 4.3 h, whereas that required for T. b. gambiense ODC was longer than 18 h. We concluded that the higher specific ODC activity and faster enzyme turnover contributed to a substantial degree to the DFMO tolerance observed in the East African T. b. rhodesiense isolates.

Full Text

The Full Text of this article is available as a PDF (291.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacchi C. J., Garofalo J., Ciminelli M., Rattendi D., Goldberg B., McCann P. P., Yarlett N. Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. Biochem Pharmacol. 1993 Aug 3;46(3):471–481. doi: 10.1016/0006-2952(93)90524-z. [DOI] [PubMed] [Google Scholar]
  2. Bacchi C. J., Garofalo J., Mockenhaupt D., McCann P. P., Diekema K. A., Pegg A. E., Nathan H. C., Mullaney E. A., Chunosoff L., Sjoerdsma A. In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Mol Biochem Parasitol. 1983 Mar;7(3):209–225. doi: 10.1016/0166-6851(83)90022-1. [DOI] [PubMed] [Google Scholar]
  3. Bacchi C. J., Garofalo J., Santana A., Hannan J. C., Bitonti A. J., McCann P. P. Trypanosoma brucei brucei: regulation of ornithine decarboxylase in procyclic forms and trypomastigotes. Exp Parasitol. 1989 May;68(4):392–402. doi: 10.1016/0014-4894(89)90124-0. [DOI] [PubMed] [Google Scholar]
  4. Bacchi C. J., Nathan H. C., Livingston T., Valladares G., Saric M., Sayer P. D., Njogu A. R., Clarkson A. B., Jr Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. 1990 Jun;34(6):1183–1188. doi: 10.1128/aac.34.6.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bales J. D., Jr, Harrison S. M., Mbwabi D. L., Schecter P. J. Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol. 1989 Aug;83 (Suppl 1):111–114. doi: 10.1080/00034983.1989.11812414. [DOI] [PubMed] [Google Scholar]
  6. Baltz T., Baltz D., Giroud C., Crockett J. Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 1985 May;4(5):1273–1277. doi: 10.1002/j.1460-2075.1985.tb03772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bellofatto V., Fairlamb A. H., Henderson G. B., Cross G. A. Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Mol Biochem Parasitol. 1987 Oct;25(3):227–238. doi: 10.1016/0166-6851(87)90086-7. [DOI] [PubMed] [Google Scholar]
  8. Bitonti A. J., Bacchi C. J., McCann P. P., Sjoerdsma A. Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei. Biochem Pharmacol. 1986 Jan 15;35(2):351–354. doi: 10.1016/0006-2952(86)90539-3. [DOI] [PubMed] [Google Scholar]
  9. Brun R., Kunz C. In vitro drug sensitivity test for Trypanosoma brucei subgroup bloodstream trypomastigotes. Acta Trop. 1989 Oct;46(5-6):361–368. doi: 10.1016/0001-706x(89)90048-x. [DOI] [PubMed] [Google Scholar]
  10. Cooper K. D., Shukla J. B., Rennert O. M. Polyamine compartmentalization in various human disease states. Clin Chim Acta. 1978 Jan 2;82(1-2):1–7. doi: 10.1016/0009-8981(78)90019-0. [DOI] [PubMed] [Google Scholar]
  11. Elias S., Bercovich B., Kahana C., Coffino P., Fischer M., Hilt W., Wolf D. H., Ciechanover A. Degradation of ornithine decarboxylase by the mammalian and yeast 26S proteasome complexes requires all the components of the protease. Eur J Biochem. 1995 Apr 1;229(1):276–283. [PubMed] [Google Scholar]
  12. Hamm B., Schindler A., Mecke D., Duszenko M. Differentiation of Trypanosoma brucei bloodstream trypomastigotes from long slender to short stumpy-like forms in axenic culture. Mol Biochem Parasitol. 1990 Apr;40(1):13–22. doi: 10.1016/0166-6851(90)90075-w. [DOI] [PubMed] [Google Scholar]
  13. Iten M., Matovu E., Brun R., Kaminsky R. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol. 1995 Sep;46(3):190–194. [PubMed] [Google Scholar]
  14. Kaminsky R., Chuma F., Zweygarth E. Trypanosoma brucei brucei: expression of drug resistance in vitro. Exp Parasitol. 1989 Oct;69(3):281–289. doi: 10.1016/0014-4894(89)90074-x. [DOI] [PubMed] [Google Scholar]
  15. Lanham S. M., Godfrey D. G. Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp Parasitol. 1970 Dec;28(3):521–534. doi: 10.1016/0014-4894(70)90120-7. [DOI] [PubMed] [Google Scholar]
  16. Mehlitz D., Brinkmann U., Haller L. Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part I. Review of literature and description of the study areas. Tropenmed Parasitol. 1981 Sep;32(3):129–133. [PubMed] [Google Scholar]
  17. Milord F., Loko L., Ethier L., Mpia B., Pépin J. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):473–477. doi: 10.1016/0035-9203(93)90044-q. [DOI] [PubMed] [Google Scholar]
  18. Murakami Y., Matsufuji S., Miyazaki Y., Hayashi S. Destabilization of ornithine decarboxylase by transfected antizyme gene expression in hepatoma tissue culture cells. J Biol Chem. 1992 Jul 5;267(19):13138–13141. [PubMed] [Google Scholar]
  19. Pegg A. E., McCann P. P. Polyamine metabolism and function. Am J Physiol. 1982 Nov;243(5):C212–C221. doi: 10.1152/ajpcell.1982.243.5.C212. [DOI] [PubMed] [Google Scholar]
  20. Phillips M. A., Coffino P., Wang C. C. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition. J Biol Chem. 1987 Jun 25;262(18):8721–8727. [PubMed] [Google Scholar]
  21. Phillips M. A., Wang C. C. A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine. Mol Biochem Parasitol. 1987 Jan 2;22(1):9–17. doi: 10.1016/0166-6851(87)90064-8. [DOI] [PubMed] [Google Scholar]
  22. Rogers S., Wells R., Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science. 1986 Oct 17;234(4774):364–368. doi: 10.1126/science.2876518. [DOI] [PubMed] [Google Scholar]
  23. Svensson F., Ceriani C., Wallström E. L., Kockum I., Algranati I. D., Heby O., Persson L. Cloning of a trypanosomatid gene coding for an ornithine decarboxylase that is metabolically unstable even though it lacks the C-terminal degradation domain. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):397–402. doi: 10.1073/pnas.94.2.397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tabor C. W., Tabor H. Polyamines. Annu Rev Biochem. 1984;53:749–790. doi: 10.1146/annurev.bi.53.070184.003533. [DOI] [PubMed] [Google Scholar]
  25. Van Nieuwenhove S., Schechter P. J., Declercq J., Boné G., Burke J., Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg. 1985;79(5):692–698. doi: 10.1016/0035-9203(85)90195-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES